Filtros de búsqueda

Lista de obras de Roberto Latagliata

"Real-life" results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia

artículo científico publicado en 2010

A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry.

artículo científico publicado en 2017

A long-term study of young patients with essential thrombocythemia treated with anagrelide.

artículo científico publicado en 2004

AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance

artículo científico publicado en 2011

Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients

artículo científico publicado en 2013

Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival

Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN.

artículo científico publicado en 2015

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis

artículo científico publicado en 2017

Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors

artículo científico publicado en 2017

Cardiovascular events and intensity of treatment in polycythemia vera

artículo científico publicado en 2012

Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC).

artículo científico publicado en 2015

Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion

artículo científico publicado en 2010

Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events.

artículo científico publicado en 2018

Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib

artículo científico publicado en 2011

Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase

artículo científico publicado en 2015

Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome

Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey

scientific article published on 18 June 2020

Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin

artículo científico publicado en 2008

Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation.

artículo científico publicado en 2005

Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?

scientific article published on 13 June 2018

Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients.

artículo científico publicado en 2009

Comparison of JAK2(V617F) -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology

artículo científico publicado en 2017

Complete clearance of Ph+ metaphases after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemia

artículo científico publicado en 2012

Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront.

artículo científico publicado en 2015

Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose

artículo científico publicado en 2010

Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life

artículo científico publicado en 2010

Dasatinib first-line: Multicentric Italian experience outside clinical trials

artículo científico publicado en 2015

Dasatinib in the management of lymphoid blast crisis of Philadelphia-positive chronic myeloid leukemia with multiple extra-medullary and intracranial localizations

artículo científico publicado en 2009

Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib

scientific article published on 25 June 2011

Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results

artículo científico publicado en 2009

Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.

artículo científico publicado en 2015

Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.

artículo científico publicado en 2012

Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia

artículo científico publicado en 2008

Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a lar

artículo científico publicado en 2018

Digital droplet PCR at the time of TKI discontinuation in chronic-phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome

scientific article published on 05 August 2019

Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response

artículo científico publicado en 2015

Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients

scholarly article by Francesca Palandri et al published November 2018 in Leukemia Research

Early and late complications related to central venous catheters in hematological malignancies: a retrospective analysis of 1102 patients

artículo científico

Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation

artículo científico publicado en 2009

Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia.

artículo científico publicado en 2007

Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis

scientific article published on 14 June 2019

Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study

artículo científico publicado en 2017

Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia

artículo científico publicado en 2011

Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment

artículo científico publicado en 2005

Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis.

artículo científico publicado en 2002

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial

artículo científico publicado en 2017

Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.

artículo científico publicado en 2018

Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes

artículo científico publicado en 2010

Erythropoietin Treatment in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Frontline Imatinib who Developed Late Anemia

artículo científico publicado en 2020

Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients.

artículo científico publicado en 2010

FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysis

artículo científico publicado en 2013

Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia

artículo científico publicado en 2016

ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems

artículo científico publicado en 2017

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome

artículo científico publicado en 2016

Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up

artículo científico publicado en 2010

Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study

artículo científico publicado en 2013

Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib

scientific article published on 07 June 2019

Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia

artículo científico publicado en 2012

Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party

artículo científico publicado en 2007

Impact of exclusion criteria for the DASISION and ENESTnd trials in the front-line treatment of a 'real-life' patient population with chronic myeloid leukaemia

artículo científico publicado en 2015

Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib

artículo científico publicado en 2014

Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia

artículo científico publicado en 2012

Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia

artículo científico publicado en 2016

Influence of time to complete remission and duration of all-trans retinoic acid therapy on the relapse risk in patients with acute promyelocytic leukemia receiving AIDA protocols

artículo científico publicado en 2012

Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with ATRA and chemotherapy.

artículo científico publicado en 2015

Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?

artículo científico publicado en 2014

Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy

artículo científico publicado en 2013

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

artículo científico publicado en 2019

Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia

artículo científico publicado en 2008

Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib.

artículo científico publicado en 2017

Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase

artículo científico publicado en 2011

Management and outcome of 11 pregnancies in women with polycythemia vera

scientific article published on 08 April 2019

Management of acute promyelocytic leukemia in the elderly

artículo científico publicado en 2013

Management of the 2009 A/H1N1 influenza pandemic in patients with hematologic diseases: a prospective experience at an Italian center

artículo científico publicado en 2011

Myelodysplastic syndromes in patients under 50 years old: a single institution experience.

artículo científico publicado en 2005

Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocytic leukemia cells

artículo científico publicado en 2014

Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia

artículo científico publicado en 2002

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice

scientific article published on 28 February 2019

Ocular side effects in chronic myeloid leukemia patients treated with imatinib

artículo científico publicado en 2007

Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry

artículo científico publicado en 2009

Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series

artículo científico publicado en 2017

Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib

artículo científico publicado en 2005

Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience

artículo científico publicado en 2011

Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib

artículo científico publicado en 2017

Prognostic features of patients with myelodysplastic syndromes aged < 50 years: update of a single-institution experience

artículo científico publicado en 2012

Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment

scientific article published on 23 January 2020

Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians

artículo científico publicado en 2011

RISK FACTORS FOR PROGRESSION TO BLAST PHASE AND OUTCOME IN 589 PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB: REAL WORLD DATA

scientific article published on 09 April 2020

Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study.

artículo científico publicado en 2016

Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy

artículo científico publicado en 2019

Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients

artículo científico publicado en 2010

Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients

artículo científico publicado en 2016

Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia

artículo científico publicado en 2017

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

artículo científico publicado en 2021

Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.

artículo científico publicado en 2016

Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients

artículo científico publicado en 2018

Second primary malignancy in myelofibrosis patients treated with ruxolitinib

artículo científico publicado en 2020

Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.

artículo científico publicado en 2009

Second-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukaemia (CML).

artículo científico publicado en 2014

Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).

artículo científico publicado en 2013

Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients

artículo científico publicado en 2016

Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia.

artículo científico publicado en 2015

Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide ⬇️

artículo científico publicado el 12 de enero de 2011

Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms

article

The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials

artículo científico publicado en 2017

The risk of infections in patients with myelodysplastic syndromes in 2016.

artículo científico publicado en 2016

Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem

artículo científico publicado en 2002

Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life

artículo científico publicado en 2017

Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors

scientific article published on 30 May 2019

Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodyplastic syndromes

artículo científico publicado en 2005

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda